EHA: AbbVie, Roche cement Venclexta’s place in AML with survival win

EHA: AbbVie, Roche cement Venclexta's place in AML with survival win

ADA: Lilly’s Trulicity tops Ozempic at keeping patients compliant, real-world data show

ADA: Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data show

How to get to $11B? For Sanofi and Regeneron’s Dupixent, 5 new approvals would help

How to get to $11B? For Sanofi and Regeneron's Dupixent, 5 new approvals would help

ADA: AstraZeneca’s diabetes-fighter Farxiga cuts risk of fast decline in kidney function

ADA: AstraZeneca's diabetes-fighter Farxiga cuts risk of fast decline in kidney function

AbbVie’s Skyrizi bests Novartis’ Cosentyx in head-to-head psoriasis match

AbbVie's Skyrizi bests Novartis' Cosentyx in head-to-head psoriasis match

How to Handle the Pressure of Being a Manager Right Now

How to Handle the Pressure of Being a Manager Right Now

What Leadership Needs in the Decade Ahead

What Leadership Needs in the Decade Ahead

Alexion bets $1.4B on Portola and its laggard bleeding drug Andexxa

Alexion bets $1.4B on Portola and its laggard bleeding drug Andexxa

Novo’s Nash play takes shape

Novo’s Nash play takes shape

One Step Closer: FTC Clears AbbVie and Allergan’s $63 Billion Merger

One Step Closer: FTC Clears AbbVie and Allergan's $63 Billion Merger